Abstract - 2018 - Research and Practice in Thrombosis and Haemostasis
purpura bleeding :: Article Creator Clinical Decision-Making In ITP: Timing Treatment Initiation And Therapy Goals An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions based on platelet count, bleeding symptoms, and comorbidities, with options ranging from observation to urgent therapies like steroids or IVIG, and longer-term approaches tailored to patient health, treatment goals, and lifestyle considerations. Once immune thrombocytopenic purpura (ITP) is diagnosed and other causes of thrombocytopenia have been excluded, treatment decisions depend on the patient's platelet count, symptoms, and comorbidities. If a patient has a platelet count above 20,000 to 30,000 without active bleeding, treatment may not be necessary—close monitoring might be sufficient. However, if there is any evidence of bleeding (e.G., nosebleeds, hemorrhoid-related bleeding, or petechiae), treatment...